Cabazitaxel as salvage treatment for cisplatin-resistant germ cell cancer. - CabaReGeCe

Oslo University Hospital - Cancer Department0 个研究点目标入组 29 人开始时间: 2014年7月8日最近更新: 2020年11月23日

适应症

试验速览

暂无简介。

•-Male patients = 18 years old
•-Histologically verified metastatic GCC (germ cell cancer of the testicle or extragonadal GCC originating from retroperitoneum or mediastinum)
•-Disease progression during cisplatin-based chemotherapy or
•Disease progression or relapse after high-dose chemotherapy or
•Disease progression or relapse after at least 2 different platin-based regimens
•-ECOG Performance Status (PS): 0-2
•-Signed written informed consent
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 29
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•-Systemic antitumor treatment within 21 days before study entry
•-Simultaneous radiotherapy to the only target lesion
•-Patients with unstable angina pectoris, myocardial infarction = 6 months prior to first study treatment, congestive heart failure NYHA III-IV or serious uncontrolled cardiac arrhythmias
•-Patients with an active or uncontrolled infection
•-Patients who have a history of another primary malignancy and are off treatment for = 3 years, with the exception of non-melanoma skin cancer
•-Active infection requiring systemic antibiotic-, anti-viral-, or antifungal medication
•-Neuropathy = Grade 2

发起方

Oslo University Hospital - Cancer Department